2021 American Society of Hematology Annual Meeting*

Download All
December 11-14, 2021; Atlanta, Georgia
Expert faculty review and share their insights and perspectives on key findings in lymphomas and CLL presented at the 2021 ASH Annual Meeting.
John M. Burke, MD
Peter Martin, MD

Lymphomas and Chronic Lymphocytic Leukemia

Slidesets Mosunetuzumab, a CD20 x CD3 Bispecific Antibody, in R/R Follicular Lymphoma With ≥2 Previous Therapies: Pivotal Phase II Trial Results
Slidesets Phase II ELARA: Extended Follow-up and Subgroup Analysis of Tisagenlecleucel in High-Risk R/R Follicular Lymphoma
Slidesets Primary Analysis of ZUMA-7: Randomized Phase III Trial of 2L Axicabtagene Ciloleucel vs Standard of Care in Relapsed/Refractory Large B-Cell Lymphoma
Slidesets Pivotal Phase II Trial of Valemetostat, an EZH1/EZH2 Inhibitor, in Patients With R/R Adult T-Cell Leukemia/Lymphoma
Slidesets ELEVATE-RR: Characterization of BTKi-Related AEs in Acalabrutinib vs Ibrutinib in Previously Treated CLL
Slidesets CITADEL-205: Phase II Study of Parsaclisib in Patients With BTK Inhibitor–Naive Relapsed/Refractory Mantle Cell Lymphoma
Slidesets Phase II Study of Novel BTK Inhibitor MK-1026 in Patients With R/R CLL/SLL
Slidesets 3-Yr Follow-up of ASCEND Phase III Trial: Acalabrutinib vs Idelalisib/Rituximab or Bendamustine/Rituximab in R/R CLL
Slidesets Phase III SEQUOIA Trial of Zanubrutinib vs Bendamustine and Rituximab in Previously Untreated CLL/SLL
Slidesets Prospective Study Evaluating MRD and CT Imaging Surveillance Following First-line Treatment in Patients With DLBCL
Slidesets Alliance 051701: Randomized Phase II/III Trial of DA-EPOCH-R ± Venetoclax in Patients With Previously Untreated Double-Hit Lymphoma
Slidesets CAPTIVATE MRD Cohort: 2-Yr Postrandomization Efficacy and Safety With First-Line Ibrutinib + Venetoclax in CLL
Slidesets GLOW: MRD Outcomes After First-line Fixed-Duration Ibrutinib + Venetoclax vs Chlorambucil + Obinutuzumab for Older/Unfit Patients With CLL
Slidesets CITADEL-203 Phase II Study of the PI3Kδ Inhibitor Parsaclisib in Patients With Relapsed/Refractory Follicular Lymphoma
Slidesets TRANSFORM: Lisocabtagene Maraleucel vs Salvage Chemotherapy Followed by ASCT as Second-Line Treatment in Relapsed/Refractory Large B-Cell Lymphoma
Slidesets POLARIX Trial of Polatuzumab Vedotin + R-CHP VS R-CHOP in Patients With Previously Untreated DLBCL
Slidesets Phase III BELINDA Trial of Tisagenlecleucel vs Standard of Care as Second-line Treatment for R/R Aggressive B-Cell Non-Hodgkin Lymphoma

Expert faculty review and share their insights and perspectives on key studies on the management of lymphomas and CLL presented at the 2021 American Society of Hematology Annual Meeting.

John M. Burke, MD Peter Martin, MD Physicians: maximum of 1.25 AMA PRA Category 1 Credits™ Released: May 10, 2022 Expired: No longer available for credit
Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie
AstraZeneca
Daiichi Sankyo, Inc.
GlaxoSmithKline
Incyte Corporation
Jazz Pharmaceuticals, Inc.
Merck Sharp & Dohme Corp.
Novartis Pharmaceuticals Corporation

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings